Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05486468 · ClinicalTrials.gov registry record · Phase 3
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
A Phase 3 study of Uveitis and Uveitis, Posterior, sponsored by Texas Retina Associates.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05486468: Recruiting Phase 3 study of Uveitis and Uveitis, Posterior, sponsored by Texas Retina Associates.
NCT05486468 is a Phase 3 study of Uveitis and Uveitis, Posterior that is actively recruiting participants, run by Texas Retina Associates. The registered enrollment target is 30 participants, below the 616-participant average among 19 other Uveitis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05486468, a Phase 3 study of Uveitis and Uveitis, Posterior, is actively recruiting participants, sponsored by Texas Retina Associates.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)
Primary Outcome
The primary endpoint of recurrence rate of uveitis will be assessed at the 6-month visit. The clinical definition of intraocular inflammation recurrence is (1) a 2-step or more increase in number of cells in the anterior chamber per high-powered field (x1.6 using a 1-mm beam), (2) a 2-step or more increase in vitreous haze, or (3) a deterioration in BCVA of 15 letters or more. In each case, the etiology of the change must be only due to noninfectious uveitis.
Conditions Studied
Interventions
- DRUG Yutiq 0.18 MG Drug Implant
- OTHER Sham Injection
Study Locations (1)
Texas
- Texas Retina Associates - Plano
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-10-05 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
What NCT05486468 shows while recruiting
NCT05486468 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 616-participant average among 19 other Uveitis trials with a reported enrollment target (95% lower).
The record links to 4 conditions, with Uveitis appearing as the primary indexed condition, and to 2 interventions - of which Yutiq 0.18 MG Drug Implant is the first listed.
NCT05486468 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05486468 about?
NCT05486468 is a clinical study titled "The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment". The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)
What is the current status of trial NCT05486468?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2022-10-05. Estimated completion is 2026-12.
What conditions does trial NCT05486468 study?
This clinical trial studies the following conditions: Uveitis, Uveitis, Posterior, Uveitis, Intermediate, Uveitis, Anterior.
What interventions are being tested in trial NCT05486468?
The interventions under investigation include: Yutiq 0.18 MG Drug Implant (DRUG), Sham Injection (OTHER).
Who is sponsoring clinical trial NCT05486468?
This trial is sponsored by Texas Retina Associates, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05486468 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05486468's enrollment target sits among peer trials
30 17th of 19 higher than 3 of 19 other Uveitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
ACTIVE NOT RECRUITING · Phase 3
-
Study of Difluprednate in the Treatment of Uveitis
COMPLETED · Phase 3
-
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
COMPLETED · Phase 3
-
PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
COMPLETED · Phase 3
-
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
COMPLETED · Phase 3
-
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI